TMDX
vs
S&P 500

Over the past 5 years, TMDX has significantly outperformed S&P 500, delivering a return of 288% compared to the S&P 500's 83% growth.

Stocks Performance
TMDX vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
TMDX vs S&P 500

Performance Comparison
TMDX vs S&P 500

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
TMDX
Transmedics Group Inc
4%
-48%
-55%
-6%
288%
209%
209%
S&P 500
Market Index
-2%
4%
7%
27%
83%
194%
402%

Transmedics Group Inc
Glance View

Market Cap
2.3B USD
Industry
Health Care

TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists. Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.

TMDX Intrinsic Value
40.75 USD
Overvaluation 41%
Intrinsic Value
Price

See Also

Back to Top